UroGen Pharma
UroGen Pharma Logo
About UroGen Pharma
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for urological diseases, particularly urothelial and specialty cancers. The company leverages proprietary technologies such as RTGel, a reverse thermal gelation hydrogel, to enhance the therapeutic profiles of existing drugs. Its portfolio includes Jelmyto, approved for the treatment of low-grade upper tract urothelial cancer, and a pipeline of investigational therapies targeting non-muscle invasive bladder cancer and other urological malignancies. UroGen Pharma aims to transform the standard of care in uro-oncology through innovative drug delivery and treatment solutions.
Address
400 Alexander Park Drive, 4th Floor
Princeton, 08540
United States
Year founded
2004
Number of employees
200-300
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
